Welcome Guest |
Contact Us | Feedback      
             
 21 October 2017
Username
Password
New User Sign-Up | Forgot Password
 
 
ANTI-PLATELET - COMBO THERAPY for prophylaxis IS NOT GOOD: New study
 
     
  Clopidogrel / Aspirin compo anti plated Therapy - No benefit; but may harm those high-risk patients with Diabetes and other CVD risks.  
   
  May 2006 DOC News (Published by American Diabetes Association)  
   
  "The addition of Clopidogrel (Plavix, Sanofi-Aventis/Bristol-Myers Squibb) to a daily low-dose aspirin regimen does not significantly reduce the incidence of death, heart attack, or stoke among people with diabetes or other cardiovascular risk factors, according to research presented at the American College of cardiology (ACC) Scientific Session, held March 11-14 in Atlanta."  
   
  "While the combination benefits people with a history of cardiovascular disease (CVD), Clopidogrel appears to be linked to more harmful side effects in people who have only CVD risk factors, say investigators in the Clopidogrel for High Athero-thrombotic Risk and Ischemia Stabilization, Management and Avoidance (CHARISMA) study."  
   
  "Combination Therapy may be useful in a large, new group of patients-those with established cardiovascular disease-but offers no benefit whatsoever in patients only having risk factors for developing vascular disease, "says lead investigator Deepak L. Bhatt, MD, director of cardiovascular clinical trials at the Cleveland Clinic on Ohio."  
   
  "Yet the addition of clopidogrel appears to increase the risk of cardiovascular events for people with risk factors but not established disease. Of the 3,284 patients with multiple cardiovascular risk factors, 6.6% of those who took aspirin plus Clopidogrel died or had a heart attack or stoke, compared with 5.5% of those who received aspirin plus placebo. Cardiac-related mortality nearly doubled among those taking clopidogrel compared with those on aspirin alone-2.2% of those on placebo died, compared with 3.9% of those in clopidogrel."  
   
  THE CHARISMA TRIAL "ARGUES AGAINST THE USE OF DUAL ANTI-PLATELET THERAPY" IN PATIENTS WITH MULTIPLE RISK FACTORS.  
   
  "Results from CHARISMA were published March 12 in the online edition of the New England Journal of Medicine as they were being presented at ACC."  
   
  "The American Heart Association on March 15 issued a statement saying that the CHARISMA trial failed to support the use of clopidogrel in patients with stable cardiovascular disease or as a preventive measure in those at high risk for CVD."  
   
  For full details log on to www.diabetes.org/docnews  
   
Blogspot
Prof B.M.Hegde Health Mongering
 News & Events
World Diabetes Day 2015 
Some Thoughts on quantum healing 
International Conference 
Holistic Healing 
Dinamani Article-2012 
INSULIN PLANT
B.M.Hegde LIFETIME ACHIEVEMENT AWARD
HOSPITAL-HAZARDS
HOSPITAL STAY RISKIER THAN FLYING, SAYS WHO
FRAUD IN GHOST WRITING
K - YOGA SCHOOL
LIFETIME ACHIEVEMENT AWARD
Click here for more
 Book Launch
Prophetic Thoughts and Articles on Health & Disease Body & MindBody Mind
GOLDEN JUBILEE YEAR - MEDICAL LECTURE SERIES
HEALTH CARE, INDIA - VISION 2010
The program was well attended by some members of the British Parliament ...
ANTI-PLATELET - COMBO THERAPY
DIABETIC LIVE LONGER
THE SCANDAL OF POOR MEDICAL RESEARCH
World Diabetes Day observed at VHS Hospital
Testimonial
Journal Article
Medical History
PEMFE in the Diabetic Foot
 
 
 
 
 
 
 Video
Thanks to Jaya Tv.
Concieved Designed & Maintained By HealthTrack Info Solutions Copyright © 2004 PubmedInfo.com All rights reserved.